Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial.

Conclusion: Sorafenib after metastasectomy did not improve RFS, but surgery in selected patients potentially improves survival. At a median follow-up of 42 months, 47% in the observation arm are relapse-free Clinical trial registration: www.clinicaltrials.gov identifier is NCT0144480. PMID: 33472450 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research